Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 20190910083343
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Overall survival (OS) is currently the primary
criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant
medical oncologist at the National University Hospital, Singapore, details the
crucial role played by tumour response in evaluating treatment efficacy, with a
focus on the multiple kinase inhibitor lenvatinib in the treatment of
hepatocellular carcinoma (HCC).
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Hepatology - Malaysia digital copy today!
Treatment with nidufexor led to significantly reduced serum alanine aminotransferase (ALT) levels and hepatic fat fraction in patients with nonalcoholic steatohepatitis (NASH), according to a phase II study presented at ILC 2020.
A trivalent vaccine against hepatitis (hep B) is safe and effectively elicits robust immune response compared with a monovalent Hep B vaccine, according to the PROTECT and CONSTANT studies presented during the 2020 digital ILC.